Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala Purchases 3,195 Shares

Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala acquired 3,195 shares of Zura Bio stock in a transaction on Monday, April 22nd. The shares were bought at an average cost of $3.13 per share, for a total transaction of $10,000.35. Following the completion of the purchase, the executive vice president now directly owns 3,195 shares of the company’s stock, valued at $10,000.35. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Zura Bio Price Performance

Shares of NASDAQ ZURA opened at $3.62 on Friday. The business’s 50 day moving average is $3.19 and its two-hundred day moving average is $4.03. Zura Bio Limited has a 1-year low of $2.00 and a 1-year high of $14.00.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer reissued an “outperform” rating and set a $16.00 price objective (down from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $16.40.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Forefront Analytics LLC grew its stake in shares of Zura Bio by 46.8% during the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after buying an additional 6,765 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Zura Bio by 15.4% during the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock valued at $8,518,000 after buying an additional 244,000 shares during the last quarter. Lynx1 Capital Management LP bought a new position in shares of Zura Bio during the third quarter valued at approximately $65,000. Eisler Capital US LLC bought a new position in shares of Zura Bio during the third quarter valued at approximately $660,000. Finally, Silverarc Capital Management LLC grew its stake in shares of Zura Bio by 152.5% during the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock valued at $2,667,000 after buying an additional 244,040 shares during the last quarter. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.